On June 22, 2020 Beijing’s SinocellTech reported that it completed a $181 million IPO on Shanghai’s STAR Board and nearly tripled in price during its initial trading session (Press release, Sinocelltech, JUN 22, 2020, View Source [SID1234561390]). The offering was priced at 25.64 RMB per share and ended its first session at 73.07 RMB, giving SinocellTech a market capitalization of nearly $4.5 billion. Sinocelltech is a biotech company that discovers and develops mAbs, recombinant proteins and vaccine products. The company has 23 products in its pipeline, including 21 novel differentiated drugs and two biosimilars.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!